You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,539,337

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,539,337

Title:	Compositions comprising two different populations of polymer-active agent conjugates
Abstract:	Compositions comprising two different populations of polymer-active agent conjugates, wherein the weight average molecular weight of the polymers associated with each population is different, are provided. Also provided are methods preparing such compositions and methods for administering such compositions.
Inventor(s):	Bossard; Mary J. (Madison, AL)
Assignee:	Nektar Therapeutics (San Francisco, CA)
Application Number:	11/009,304
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,539,337
Patent Claims:	1. A composition comprising: a first population of polymer-active agent conjugates, wherein each polymer in the first population of polymer-active agent conjugates has a weight average molecular weight; and a second population of polymer-active agent conjugates, wherein each polymer in the second population of polymer-active agent conjugates has a weight average molecular weight, wherein the weight average molecular weight of each polymer in the first population is in the range of from about 100 Daltons to less than 20,000 Daltons, and the weight average molecular weight of each polymer in the second population is in the range of from greater than 100 Daltons to about 120,000 Daltons, wherein the weight average molecular weight of each polymer in the first population is different from the weight average molecular weight of each polymer in the second population. 2. The composition of claim 1, wherein the weight average molecular weight of each polymer in the first population is in the range of from about 100 Daltons to less than 20,000 Daltons, and the weight average molecular weight of each population in the second population is in the range of from greater than 20,000 Daltons to about 100,000 Daltons. 3. The composition of claim 2, wherein the weight average molecular weight of each polymer in the first population is in the range of from about 1,000 Daltons to about 15,000 Daltons, and the weight average molecular weight of each polymer in the second population is in the range of from greater than about 25,000 Daltons to about 50,000 Daltons. 4. The composition of claim 3, wherein the weight average molecular weight of each polymer in the first population is in the range of from about 2,500 Daltons to about 10,000 Daltons, and the weight average molecular weight of each polymer in the second population is in the range of greater than 30,000 Daltons to about 40,000 Daltons. 5. The composition of claim 4, wherein the weight average molecular weight of each polymer in the first population is about 5,000 Daltons, and the weight average molecular weight of each polymer in the second population is in the range of from about 30,000 Daltons to about 40,000 Daltons. 6. The composition of claim 1, wherein the absolute difference between the weight average molecular weight of each polymer in the first population and the weight average molecular weight of each polymer in the second population is from about 500 Daltons to about 100,000 Daltons. 7. The composition of claim 1, wherein the absolute difference between the weight average molecular weight of each polymer in the first population and the weight average molecular weight of each polymer in the second population is from about 2,000 Daltons to about 100,000 Daltons. 8. The composition of claim 1, wherein the absolute difference between the weight average molecular weight of each polymer in the first population and the weight average molecular weight of each polymer in the second population is from about 10,000 Daltons to about 100,000 Daltons. 9. The composition of claim 1, wherein the absolute difference between the weight average molecular weight of each polymer in the first population and the weight average molecular weight of each polymer in the second population is from about 20,000 Daltons to about 100,000 Daltons. 10. The composition of claim 1, wherein the absolute difference between the weight average molecular weight of each polymer in the first population and the weight average molecular weight of each polymer in the second population is from about 30,000 Daltons to about 100,000 Daltons. 11. The composition of claim 1, wherein the absolute difference between the weight average molecular weight of each polymer in the first population and the weight average molecular weight of each polymer in the second population is from about 20,000 Daltons to about 40,000 Daltons. 12. The composition of claim 1, wherein the absolute difference between the weight average molecular weight of each polymer in the first population and the weight average molecular weight of each polymer in the second population is from about 25,000 Daltons to about 35,000 Daltons. 13. The composition of claim 1, wherein the first and second populations of polymer-active agent conjugates has a molar ratio between them of from about 1000:1 to about 100:1. 14. The composition of claim 1, wherein the first and second populations of polymer-active agent conjugates has a molar ratio between them of from about 100:1 to about 10:1. 15. The composition of claim 1, wherein the first and second populations of polymer-active agent conjugates has a molar ratio between them of from about 10:1 to about 1:1. 16. The composition of claim 1, wherein the first and second populations of polymer-active agent conjugates has a molar ratio between them of from about 1:1 to about 1:10. 17. The composition of claim 1, wherein the first and second populations of polymer-active agent conjugates has a molar ratio between them of from about 1:10 to about 1:100. 18. The composition of claim 1, wherein the first and second populations of polymer-active agent conjugates has a molar ratio between them of from about 1:100 to about 1:1000. 19. The composition of claim 1, wherein each polymer in the first and second populations of polymer-active agent conjugates is independently selected from the group consisting of a poly(alkylene oxide), poly(vinyl pyrrolidone), poly(vinyl alcohol), polyoxazoline, poly(acryloylmorpholine), and poly(oxyethylated polyols). 20. The composition of claim 1, wherein each polymer is a poly(ethylene glycol). 21. The composition of claim 20, wherein each poly(ethylene glycol) is terminally capped with an end-capping moiety. 22. The composition of claim 21, wherein each end-capping moiety is independently selected from the group consisting alkyloxy, substituted alkyloxy, alkenyloxy, substituted alkenyloxy, alkynyloxy, substituted alkynyloxy, aryloxy, substituted aryloxy, and hydroxy. 23. The composition of claim 22, wherein the end-capping moiety is hydroxy. 24. The composition of claim 22, wherein each end-capping moiety is alkoxy. 25. The composition of claim 24, wherein each alkoxy is methoxy. 26. The composition of claim 1, wherein each polymer in the first and second populations of polymer-active agent conjugates independently has a structure selected from the group consisting of homopolymer, alternating copolymer, random copolymer, block copolymer, alternating tripolymer, random tripolymer, and block tripolymer. 27. The composition of claim 1, wherein each of the polymer-active agent conjugates in the first population comprises a single polymer attached to a single active agent. 28. The composition of claim 1, wherein each of the polymer-active agent conjugates in the second population comprises a single polymer attached to a single active agent. 29. The composition of claim 28, wherein the poly(ethylene glycol) is linear. 30. The composition of claim 1, wherein each of the polymer-active agent conjugates in both the first and second populations comprises a single polymer attached to a single active agent. 31. The composition of claim 30, wherein the polymer is a poly(ethylene glycol). 32. The composition of claim 1, wherein the active agent has erythropoietic activity. 33. The composition of claim 1, wherein the active agent is erythropoietin. 34. The composition of claim 33, wherein the erythropoietin is recombinantly derived. 35. The composition of claim 1, wherein the active agent is a small molecule. 36. The composition of claim 35, wherein the liquid diluent is selected from the group consisting of bacteriostatic water for injection, dextrose 5% in water, phosphate-buffered saline, Ringer's solution, saline solution, sterile water, deionized water, and combinations thereof. 37. The composition of claim 1, wherein the active agent is a peptide. 38. The composition of claim 1, wherein the active agent is a protein. 39. The composition of claim 1, further comprising a pharmaceutically acceptable excipient. 40. The composition of claim 39, wherein the excipient is a sugar. 41. The composition of claim 39, in lyophilized form. 42. The composition of claim 39, housed in a glass vial. 43. A method for delivering a pharmaceutical preparation comprising the step of administering to a patient a therapeutically effective amount of the composition of claim 39. 44. The composition of claim 1, further comprising a liquid diluent. 45. The composition of claim 1, in unit dosage form. 46. A gel comprising the composition of claim 1.

Details for Patent 9,539,337

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2023-12-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.